Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2019 Filed Feb 26, 2019 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 20,295 | $109.34 | $2,219,055.30 |
DisclosureSEC source: 0001127602-19-008330 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 24,008 | $88.05 | $2,113,904.40 |
DisclosureSEC source: 0001127602-19-008330 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,212 | $144.67 | $320,010.04 |
DisclosureSEC source: 0001127602-19-008322 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,644 Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,997 | $144.67 | $288,905.99 |
DisclosureSEC source: 0001127602-19-008322 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,856 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 69,743 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-19-008322 · form4.xml · derivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,743 Underlying: Common Stock · 69,743 shares Expires 2024-02-22 F2 · derivative.exercise_date: Stock options vest as follows: 17,435 options vest one (1) year from the date of grant, 17,436 options vest two (2) years from the date of grant, 17,436 options vest three (3) years from the date of grant, and 17,436 options vest four (4) years from the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 16,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008322 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,853 F1 · security: Consists of 16,357 unvested restricted stock units that vest as follows: 4,089 shares vest one (1) year from the date of issuance, 4,089 shares vest two (2) years from the date of issuance, 4,089 shares vest three (3) years from the date of issuance, and 4,090 shares vest four (4) years from the date of issuance. Read SEC document |
| February 14, 2019 Filed Feb 26, 2019 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008322 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,496 Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 17:59 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 29,120 | $119.39 | $3,476,636.80 |
DisclosureSEC source: 0001127602-19-003324 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,071 Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 17:59 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 68,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-003324 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,191 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 26, 2016. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 14:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 25,000 | $115.00 | $2,875,000.00 |
DisclosureSEC source: 0001127602-19-001736 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,771 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · balance_after: On 09/24/2018, the reporting person contributed 25,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $129.43 | $25,886.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,771 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 77 | $129.24 | $9,951.10 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,971 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $129.22 | $12,922.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,048 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 186 | $129.20 | $24,031.20 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,148 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $129.19 | $12,919.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,334 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $129.17 | $25,834.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,434 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 57 | $129.16 | $7,362.12 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,634 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 157 | $129.15 | $20,276.55 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,691 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 96 | $129.15 | $12,397.92 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,848 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $129.11 | $12,911.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,944 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $129.10 | $12,910.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,044 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $129.02 | $38,706.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,144 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4 | $128.98 | $515.92 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,444 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $128.84 | $12,884.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,448 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $128.80 | $12,880.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,548 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $128.65 | $12,865.00 |
DisclosureSEC source: 0001127602-18-036014 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,648 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.82 | $12,682.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,204 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.81 | $12,681.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,304 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 324 | $126.80 | $41,083.20 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,404 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1 | $126.80 | $126.80 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,728 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 252 | $126.79 | $31,949.82 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,729 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 31 | $126.78 | $3,930.18 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,981 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $126.77 | $50,708.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,012 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 72 | $126.77 | $9,127.08 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,412 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $126.76 | $76,056.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,484 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.76 | $12,675.50 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,084 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 134 | $126.75 | $16,984.50 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,184 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.74 | $25,348.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,318 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 301 | $126.73 | $38,145.73 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,518 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 8 | $126.72 | $1,013.72 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,819 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.71 | $25,342.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,827 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.70 | $12,670.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,027 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.69 | $12,669.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,127 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.69 | $12,668.50 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,227 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.67 | $25,334.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,327 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 108 | $126.67 | $13,679.82 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,527 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 50 | $126.66 | $6,333.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,635 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.64 | $25,328.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,685 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.63 | $12,663.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,885 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.62 | $25,324.00 |
DisclosureSEC source: 0001127602-18-036008 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,985 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.